TNFRSF9 and neoplasm: CD137 signaling has been implicated in the activation of CD8+ T cells, while CD134 activity was shown to be a driver of T cell-mediated anti-tumor immunity, both having the potential to significantly improve the anti-tumorigenic effect of combinatorial targeted therapy (162).